JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) says that prescriptions for its new oral weight loss therapy, the Wegovy pill, have exceeded 3M in just five months after its U.S. launch, a milestone for a company that is struggling to outshine its rival Eli Lilly ( LLY ) in the lucrative market for obesity drugs. During an R&D event on Sunday, the Danish drugmaker said it achieved...
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) says that prescriptions for its new oral weight loss therapy, the Wegovy pill, have exceeded 3M in just five months after its U.S. launch, a milestone for a company that is struggling to outshine its rival Eli Lilly ( LLY ) in the lucrative market for obesity drugs. During an R&D event on Sunday, the Danish drugmaker said it achieved 1M prescriptions for the Wegovy pill in 10 -12 weeks of its U.S. launch earlier this year and recorded 2M additional prescriptions over the last 10 weeks. “That's in light of competition having arrived in the latter part. So if that is not acceleration, I don't know what is,” CEO Mike Doustdar added. He was referring to Eli Lilly’s ( LLY ) oral weight loss therapy, Foundayo, which entered the market in April. However, U.S. prescriptions for Foundayo have trailed those for the Wegovy pill, according to IQVIA ( IQV ) data sourced by analysts, though the U.S. drugmaker remains head and shoulders above its European rival on Wall Street. Novo ( NVO ) said that more than 80% of new prescriptions for the Wegovy pill were for patients new to the GLP-1 drug class, indicating that its once-daily therapy was expanding the overall market for obesity treatments. Last week, TD Cowen raised its 2030 global sales estimate for GLP-1 drugs to $150B from $139B, citing, among other things, a 14% contribution from oral versions of the drug class. More on Novo Nordisk A/S Novo Nordisk: The Biggest Healthcare Bargain Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event Transcript Wall Street Underestimates Novo Nordisk's GLP-1 Comeback Novo Nordisk actively seeking deals to expand pipeline, CEO says Novo Nordisk says oral Wegovy success to soften sales decline
K Wave Media ( KWM ) announced on Tuesday that its board approved the planned retirement and cancellation of 9.8M shares expected to be returned by the end of July 2026. The move is expected to reduce the company’s outstanding shares by about 13% following the termination of the KWM-Solaire deal. The share cancellation is aimed at simplifying KWM’s corporate structure. Management said the company ...
K Wave Media ( KWM ) announced on Tuesday that its board approved the planned retirement and cancellation of 9.8M shares expected to be returned by the end of July 2026. The move is expected to reduce the company’s outstanding shares by about 13% following the termination of the KWM-Solaire deal. The share cancellation is aimed at simplifying KWM’s corporate structure. Management said the company is advancing its transition toward AI infrastructure investments, including data centers and compute resources. Source: Press Release More on K Wave Media Ltd. K Wave Media terminates Solaire acquisition, to receive back 9.8 million shares Financial information for K Wave Media Ltd.
Executives in charge of Oatly Group's ( OTLY ) China operations are reviewing buying out the business. Shares of Oatly rose 3.5%. The potential buyers are trying to come to an agreement for Oatly's ( OTLY ) Greater China business as soon as this year, according to a Bloomberg report on Tuesday, which cited people familiar with the matter. Talks are ongoing and may not result in any transaction. An...
Executives in charge of Oatly Group's ( OTLY ) China operations are reviewing buying out the business. Shares of Oatly rose 3.5%. The potential buyers are trying to come to an agreement for Oatly's ( OTLY ) Greater China business as soon as this year, according to a Bloomberg report on Tuesday, which cited people familiar with the matter. Talks are ongoing and may not result in any transaction. An Oatly representative cited the company’s latest earnings in April, when it said the group is still evaluating options for the China business to accelerate growth and maximize value. Oatly ( OTLY ) has said it expects to complete the China strategic review this year. More on Oatly Oatly Group AB (OTLY) Shareholder/Analyst Call Prepared Remarks Transcript Oatly's Race Against Time: Strong Brand Meets A Dwindling Cash Runway Oatly Group AB (OTLY) Q1 2026 Earnings Call Transcript Oatly GAAP EPS of -$0.38 beats by $0.55, revenue of $228.33M beats by $13.3M Oatly Q1 2026 Earnings Preview
AIM ImmunoTech ( AIM ) on Tuesday said it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million. The offering is expected to close on or about June 10, 2026. AIM -19.5% at $0.43. In the registered direct offering, the company will issue and sell 2.55M ...
AIM ImmunoTech ( AIM ) on Tuesday said it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million. The offering is expected to close on or about June 10, 2026. AIM -19.5% at $0.43. In the registered direct offering, the company will issue and sell 2.55M shares of common stock, par value $0.001, at a purchase price of $0.5189 per share. In addition, in a concurrent private placement, the company will issue and sell an aggregate of 2.55M unregistered shares of common stock at the per share purchase price and unregistered Class J warrants to purchase up to 10.21M shares of common stock. The Class J Warrants will have an exercise price of $0.5189 per share, will be exercisable subject to stockholder approval, and will expire five years from the initial exercise date. The company intends to use the net proceeds from the offering for (i) the manufacture of clinical drug supply, (ii) the company’s current clinical trial activities, (iii) the company’s planned Phase 3 clinical trial activities, and (iv) working capital purposes. Press release More on AIM ImmunoTech AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech
Airbus SE is unsure of reaching next year’s production target for its best-selling A320 jet because Pratt & Whitney may not be able to supply enough engines, the planemaker’s chief executive officer said. For years Airbus, has had a target of building 75 of the A320 family jets every month, but the timeline for reaching that kept slipping as pandemic-related supply chain issues hindered access to ...
Airbus SE is unsure of reaching next year’s production target for its best-selling A320 jet because Pratt & Whitney may not be able to supply enough engines, the planemaker’s chief executive officer said. For years Airbus, has had a target of building 75 of the A320 family jets every month, but the timeline for reaching that kept slipping as pandemic-related supply chain issues hindered access to parts and engines. “I am frustrated with this because we had a good plan to go to rate 75 by the end of next year, and now we see that, depending on how much we’ll finally manage to get from our friends at Pratt, we might fail on this objective and fall short of the 75,” Airbus CEO Guillaume Faury said Tuesday at the Berlin Aviation Summit. The public confrontation between Airbus and one of its main suppliers is an unusual rupture in an industry that relies on just-in-time deliveries of thousands of parts used in aircraft manufacturing. The European planemaker aims to hand over about 870 jets to customers this year, a lower number than it originally hoped for because of the dispute. Airbus had said RTX Corp. ’s Pratt cannot meet its original delivery promise for narrowbody A320 engines because of the required maintenance on planes already in service. RTX declined to comment on Faury’s statement. Pratt & Whitney CEO Christopher Calio said in April that the US engine maker will “ultimately get there to where we need to be on volumes going forward.” Engines have become a flashpoint for the industry, both in terms of their performance and lack of availability. In addition, there’s an increasing sense of being dependent on just a few manufacturers, creating quasi-monopolies. Read More: Airplane Engine Makers Called Out for ‘Gouging’ at Rio Summit Airbus hasn’t seen any deferrals or cancellations of orders from airlines because of the Iran war and its fallout on global energy markets, Faury said.
Apple’s (NASDAQ: AAPL) new Siri upgrade won’t work in the EU or China for now. China is the world’s largest smartphone market. So, in China, consumers will use old apps on current Apple products. Siri works, supposedly, the way products like OpenAI’s ChatGPT do. Many of its features were teased at the Worldwide Developers Conference, ... Siri Didn’t Rescue Apple
Apple’s (NASDAQ: AAPL) new Siri upgrade won’t work in the EU or China for now. China is the world’s largest smartphone market. So, in China, consumers will use old apps on current Apple products. Siri works, supposedly, the way products like OpenAI’s ChatGPT do. Many of its features were teased at the Worldwide Developers Conference, ... Siri Didn’t Rescue Apple
US stocks rose Tuesday, extending gains to a second straight session, with chipmaker shares including Nvidia Corp. leading a broad advance. The S&P 500 Index was up 1% as of 9:49 a.m. in New York, while the Nasdaq 100 Index jumped 1.3%, led by semiconductor companies. The Philadelphia Semiconductor Index , home to chip bellwethers such as Nvidia and Advanced Micro Devices Inc. , advanced 2.2%. Tha...
US stocks rose Tuesday, extending gains to a second straight session, with chipmaker shares including Nvidia Corp. leading a broad advance. The S&P 500 Index was up 1% as of 9:49 a.m. in New York, while the Nasdaq 100 Index jumped 1.3%, led by semiconductor companies. The Philadelphia Semiconductor Index , home to chip bellwethers such as Nvidia and Advanced Micro Devices Inc. , advanced 2.2%. That puts the gauge on track for its best two-day gain in a month, following a slide Friday. Micron Technology Inc. advanced 2.9%, while Broadcom Inc. rose nearly 1%. Among other individual shares, Applied Digital jumped 9.3% after the neocloud company said it signed a 15-year take-or-pay lease with a US-based artificial intelligence hyperscaler, for 210 megawatts of critical IT load at its Delta Forge 2 campus. Meantime, JM Smucker — the biggest S&P 500 gainer — rallied 10% after organic sales and adjusted earnings per share beat expectations for the latest quarter. US stocks also got a boost after President Donald Trump renewed his claims of momentum toward ending the conflict with Iran. Investors also focused on the AI excitement that’s powered US stocks to records in recent weeks, with ChatGPT maker OpenAI confidentially filing for a US initial public offering on Monday, before SpaceX’s hotly anticipated market debut later this week. A basket of the so-called Magnificent Seven companies advanced 0.9%. “The tech-led rebound in the wake of Friday’s market rout continues amid AI earnings optimism and easing geopolitical angst, as President Trump reiterates a peace deal with Iran is imminent,” wrote Tom Essaye , founder of ‘The Sevens Report’ newsletter. Of course, options traders whipsawed by the market’s recent gyrations remain anxious that more volatility may arrive in the coming days, starting with Wednesday’s report on consumer prices. Robust jobs data has put extra focus on the inflation figures as traders speculate the Federal Reserve’s next move will be to hike interes...